Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
August 30, 2021 at 08:00 pm IST
Share
Henan Lingrui Pharmaceutical Co., Ltd. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 1,355.486 million compared to CNY 1,174.552 million a year ago. Operating income was CNY 262.082 million compared to CNY 209.143 million a year ago. Net income was CNY 219.662 million compared to CNY 177.374 million a year ago. Basic earnings per share from continuing operations was CNY 0.39 compared to CNY 0.312 a year ago.
Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.